Expression Of MRNA In Peripheral Blood Mononuclear Cells CD14 And TLR4 In Patients With Parkinson 's Disease And The Correlation Between Plasma TNF - α And IL - 6 And Non - Exercise Symptoms

This paper includes two parts:I. Expressions of CD14 mRNA and TLR4 mRNA in peripheral blood mononuclear cells in patients with Parkinson disease. Ⅱ.Correlation analysis between TNF-a, IL-6 levels and non-motor symptoms in patients with Parkinson disease.Part I Expressions of CD14 mRNA and TLR4 mRNA inperipheral blood mononuclear cells in patients with Parkinson disease.ObjectiveTo investigate the expressions of the CD 14 mRNA and TLR4 mRNA in peripheral blood mononuclear cells from patients with Parkinson disease and to explore the clinical signicance.Methods44 patients with Parkinson disease(PD group) and 37 healthy controls (normal control group) were recruited.We recorded age of onset,duration of illness and sex of all recruited patients.PD patients were examined neurologically according to the Hoehn-Yahr stages, Unified Parkinson Disease Rating Scale (UPDRS) II and UPDRS III,non-motor symptoms scale (NMSS) on "off’time. Reverse transcription-polymerase chain reaction was performed to determine the expressions of CD14 mRNA and toll-like receptor 4(TLR4) mRNA.ResultsThe expressions of CD14mRNA(1.459±0.658) 2-ΔΔCT and TLR4 mRNA (1.408±0.698) 2-ΔΔCT was significantly up-regulated (P<0.05)in Parkinson disease compared with controls((1.162±0.631) 2-ΔΔCT、 (1.122±0.557) 2-ΔΔCT).In addition, there was positive correlation between the expressions of CD 14 mRNA in Parkinson disease patients with the Hoehn-Yahr stages. Meanwhile, there was no significant correlation between the expression of CD 14 mRNA and TLR4 mRNA with other clinical scores.ConclusionsThere was positive correlation between the expressions of CD 14 mRNA in Parkinson disease patients with the Hoehn-Yahr stages, indicating CD14/TLR4 positive monocyte may be involved in the pathogenesis of the Parkinson disease.PartⅡ Correlation analysis between TNF-a, IL-6 levels and non-motor symptoms in patients with Parkinson disease.ObjectiveTumor Necrosis Factor-a (TNF-a) and Interleukin-6 (IL-6) levels in blood were tested and correlations between TNF-a and IL-6 with motor and non-motor symptoms in PD patients were evaluated.MethodsWe measured tumor necrosis factor-a (TNF-a) and interleukin-6 (IL-6) in blood samples from 41 PD patients (PD group) and 37 healthy controls (normal control group)by enzyme-linked immune sorbent assay (ELISA). All PD patients were evaluated during "off medication state, analyzed with Hoehn-Yahr stages and non-motor symptoms scales (NMSS).Motor performance were assessed with Unified Parkinson Disease Rating Scale IⅡ (UPDRS II) and Unified Parkinson Disease Rating Scale Ⅲ (UPDRS Ⅲ).ResultsTNF-a and IL-6 levels were significantly lower in PD patients than healthy controls. In PD group, IL-6 levels were negatively correlated with Hoehn-Yahr stages, UPDRS II scores and non-motor symptoms scales (r=-0.411, P=0.008; r=-0.321, P=0.041; r=-0.324, P=0.039). However, there was no correlation between IL-6 and UPDRS III scores. Moreover, no relationship was found among TNF-a and all clinical scores in PD patients.ConclusionsThese results suggest that PD patients may undergo immunological abnormalities, which may involve in the pathogenesis of Parkinson disease, especially in the performance of non-motor symptoms.